Leerink Partners Upgrades Edwards Lifesciences (NYSE:EW) to Outperform

Edwards Lifesciences (NYSE:EW) was upgraded by Leerink Partners from a “market perform” rating to an “outperform” rating in a report released on Friday, MarketBeat Ratings reports. The brokerage currently has a $101.00 price objective on the medical research company’s stock. Leerink Partners’ price objective suggests a potential upside of 22.17% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a report on Wednesday, April 1st. Royal Bank Of Canada raised their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Finally, Truist Financial increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.55.

Edwards Lifesciences Trading Down 1.4%

Edwards Lifesciences stock opened at $82.67 on Friday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12 month low of $72.30 and a 12 month high of $96.29. The stock’s 50 day simple moving average is $87.73 and its two-hundred day simple moving average is $83.88. The firm has a market cap of $47.60 billion, a PE ratio of 47.51, a P/E/G ratio of 2.07 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The business’s revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts anticipate that Edwards Lifesciences will post 3 earnings per share for the current year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,671,117.80. The trade was a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 45,577 shares of company stock valued at $3,855,527 in the last 90 days. Company insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently modified their holdings of the business. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences during the first quarter worth about $25,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $25,000. MV Capital Management Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $26,000. RMG Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $26,000. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $27,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
• Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
• Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
• Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
• Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.